Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: Identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity

被引:44
作者
Biswas, Swati [1 ]
Hazeldine, Stuart [1 ]
Ghosh, Balaram [1 ]
Parrington, Ingrid [2 ]
Kuzhikandathil, Eldo [3 ]
Reith, Maarten E. A. [2 ]
Dutta, Aloke K. [1 ]
机构
[1] Wayne State Univ, Dept Pharmaceut Sci, Detroit, MI 48202 USA
[2] NYU, Sch Med, Dept Psychiat, Millhauser Labs, New York, NY 10016 USA
[3] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA
关键词
D O I
10.1021/jm701524h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the current report, we extend the SAR study on our hybrid structure 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol further to include heterocyclic bioisosteric analogues. Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibition constants (K). Functional activity of selected compounds in stimulating GTP gamma S binding was assessed with CHO cells expressing human D2 receptors and AtT-20 cells expressing human D3 receptors. The highest binding affinity and selectivity for D3 receptors were exhibited by (-)-34 (K-i = 0.92 nM and D2/D3 = 253). In the functional GTP gamma S binding assay, (-)-34 exhibited full agonist activity with picomolar affinity for D3 receptor with high selectivity (EC50 = 0.08 nM and D2/D3 = 248). In the in vivo rotational study, (-)-34 exhibited potent rotational activity in 6-OH-DA unilaterally lesioned rats with long duration of action, which indicates its potential application in neuroprotective treatment of Parkinson's disease.
引用
收藏
页码:3005 / 3019
页数:15
相关论文
共 53 条
[21]   Dopamine D3 receptor agonists for protection and repair in Parkinson's disease [J].
Joyce, Jeffrey N. ;
Millan, Mark J. .
CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (01) :100-105
[22]   Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor [J].
Joyce, Jeffrey N. ;
Woolsey, Cheryl ;
Ryoo, Han ;
Borwege, Sabine ;
Hagner, Diane .
BMC BIOLOGY, 2004, 2 (1)
[23]   Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs [J].
Joyce, JN .
PHARMACOLOGY & THERAPEUTICS, 2001, 90 (2-3) :231-259
[24]  
KAREL P, 2004, Patent No. 6727367
[25]   MULTIPLE RECEPTORS FOR DOPAMINE [J].
KEBABIAN, JW ;
CALNE, DB .
NATURE, 1979, 277 (5692) :93-96
[26]   Inhibitory effects of talipexole and pramipexole on MPTP-Induced dopamine reduction in the striatum of C57BL/6N mice [J].
Kitamura, Y ;
Kohno, Y ;
Nakazawa, M ;
Nomura, Y .
JAPANESE JOURNAL OF PHARMACOLOGY, 1997, 74 (01) :51-57
[27]   SYNTHESIS OF THE THIAZOLONE ANALOG OF THE ACETYLCHOLINESTERASE INHIBITOR, HUPERZINE-A [J].
KOZIKOWSKI, AP ;
TUCKMANTEL, W ;
SAXENA, A ;
DOCTOR, BP .
HELVETICA CHIMICA ACTA, 1994, 77 (05) :1256-1266
[28]   The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors [J].
Kutzhikandathil, Eldo V. ;
Bartoszyk, Gerd D. .
NEUROPHARMACOLOGY, 2006, 51 (04) :873-884
[29]  
Lazareno S, 1997, Methods Mol Biol, V83, P107
[30]   Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands for visualization of brain dopamine D3 receptors [J].
Leopoldo, M ;
Lacivita, E ;
De Giorgio, P ;
Colabufo, NA ;
Niso, M ;
Berardi, F ;
Perrone, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (01) :358-365